Análise da expressão do antígeno CD83 no fibroadenoma mamário humano e no tecido adjacente by Borges, Marcus Nascimento et al.
402     Sao Paulo Med J. 2011; 129(6):402-9
Original article
Analysis of CD83 antigen expression in human breast 
fibroadenoma and adjacent tissue
Análise da expressão do antígeno CD83 no fibroadenoma mamário humano e no 
tecido adjacente
Marcus Nascimento BorgesI, Gil FacinaII, Ismael Dale Cotrin Guerreiro SilvaIII, Angela Flávia Logullo WaitzbergIV, Afonso Celso 
Pinto NazarioV
Discipline of Mastology, Department of Gynecology, Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil
aBStract
CONTEXT AND OBJECTIVE: Dendritic cell maturation is considered essential for starting an immune re-
sponse. The CD83 antigen is an important marker of dendritic cell maturation. The objectives here were to 
analyze CD83 antigen expression in human breast fibroadenoma and breast tissue adjacent to the lesion 
and to identify clinical factors that might influence this expression. 
DESIGN AND SETTING: This was a retrospective study at a public university hospital, in which 29 histo-
pathological samples of breast fibroadenoma and adjacent breast tissue, from 28 women of reproductive 
age, were analyzed. 
METHODS: The immunohistochemistry method was used to analyze the cell expression of the antigen. 
The antigen expression in the cells was evaluated by means of random manual counting using an optical 
microscope. 
RESULTS: Positive expression of the CD83 antigen in the epithelial cells of the fibroadenoma (365.52; stan-
dard deviation ± 133.13) in relation to the adjacent breast tissue cells (189.59; standard deviation ± 140.75) 
was statistically larger (P < 0.001). Several clinical features were analyzed, but only parity was shown to 
influence CD83 antigen expression in the adjacent breast tissue, such that positive expression was more 
evident in nulliparous women (P = 0.042). 
CONCLUSIONS: The expression of the CD83 antigen in the fibroadenoma was positive and greater than in 
the adjacent breast tissue. Positive expression of the antigen in the adjacent breast tissue was influenced 
by parity, and was significantly more evident in nulliparous women. 
reSUMO
CONTEXTO E OBJETIVOS: A maturação da célula dendrítica é considerada essencial para o início da 
resposta imune. O antígeno CD83 é um importante marcador da maturação da célula dendrítica. Os obje-
tivos são analisar a expressão do antígeno CD83 no fibroadenoma mamário humano e no tecido mamário 
adjacente à lesão e identificar fatores clínicos que possam influenciar esta expressão. 
TIPO DE ESTUDO E LOCAL: Este é um estudo retrospectivo, realizado em um hospital público universi-
tário, onde 29 amostras histopatológicas de fibroadenomas de mamas e de tecidos mamários adjacentes, 
de 28 mulheres em idade reprodutiva, foram analisados. 
MÉTODOS: O método de imunoistoquímica foi utilizado na análise da expressão celular do antígeno. A 
expressão do antígeno nas células foi avaliada por contagem aleatória e manual utilizando-se microcópio 
de luz. 
RESULTADOS: A expressão positiva do antígeno CD83 nas células epiteliais dos fibroadenomas (365,52; 
desvio padrão ± 133,13) em relação às células do tecido mamário adjacente (189,59; desvio padrão ± 140,75) 
foi estatisticamente superior (P < 0,001). Vários aspectos clínicos foram analisados, porém, a paridade se 
mostrou influente na expressão do antígeno CD83 no tecido mamário adjacente, onde a expressão posi-
tiva foi mais evidente nas mulheres nulíparas (P = 0,042).
CONCLUSÕES: A expressão do antígeno CD83 foi positiva e mais expressiva no fibroadenoma do que no 
tecido mamário adjacente. A expressão positiva do antígeno no tecido mamário adjacente foi influencia-
da pela paridade, sendo significativamente mais evidente nas mulheres nulíparas.
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intrODUctiOn
Fibroadenoma is the most common benign tumor in the 
human breast, especially in women younger than 35 years 
old.1 Histologically, it presents with both epithelial and con-
junctive components, and is therefore considered to be a 
mixed lesion. The principal characteristic of this lesion is 
the presence of fibrous stroma with low cellularity that lacks 
cell atypias.2
The main function and most important feature of the 
immune system is its ability to recognize microorganisms, neo-
plastic cells and other substances as foreign to the organism. This 
occurs via identification of antigens that may be recognized as 
noxious. One of the main processes in this recognition occurs 
through a specialized protein known as the major histocompat-
ibility complex (MHC); this protein has the capacity to bind pep-
tides and to present them to T cells. There are two main types of 
MHC proteins, class I and class II, which can present peptides 
to cytolytic lymphocytes (CD8+) or to auxiliary lymphocytes 
(CD4+), respectively.3
For an immune response to start, antigens have to be 
captured and presented to the lymphocytes that are specific 
for that antigen. The cells that have this capacity are denoted 
antigen-presenting cells (APC), and dendritic cells are the 
APC type that is most specialized for this function. Den-
dritic cells capture and retain external antigens to be pro-
cessed via phagocytosis. In the cytoplasm, peptides of these 
antigens react and link to MHCs. The dendritic cells then 
migrate to the secondary lymphoid organs, where the pep-
tide-MHC complexes on the cell membrane are presented to 
inactive T lymphocytes. These cells recognize the peptide-
MHC complex through their surface receptors, thus begin-
ning the immune response. 
Dendritic cell maturation is considered essential for the 
beginning of the immune response.4 This maturation is com-
pleted after interaction with the T cell and is characterized 
by loss of endocytic capacity and the expression of acces-
sory molecules that interact with the T lymphocyte receptors 
and function as costimulators, thereby increasing their adhe-
sion and signaling.5 One of these costimulatory molecules is 
called CD83 and is a marker associated with dendritic cell 
maturation,6,7 CD83 is a member of the immunoglobulin 
superfamily, and is 45 kDa in size. It is also observed in den-
dritic cells in peripheral blood.8
It is known that abnormal cell behavior can lead to emer-
gence of fibroadenoma presenting with proliferation of con-
junctive and epithelial tissues.9 The action of the immune sys-
tem against malignant tumors is evident, but little is known 
about this process in relation to benign neoplasms. Full under-
standing of the immune response mechanisms relating to neo-
plasms may open up new horizons for treating these tumors.
OBJECTIVES 
This study had two objectives: first, to immunohistochemically 
analyze the expression of CD83 in human breast fibroadenoma 
cells and adjacent normal breast tissue; and second, to analyze 
which clinical features could influence the expression of CD83 in 
these breast tissues. 
METHODS
This was a retrospective study, in which 28 women presenting 
cases of benign nodules in the breasts were selected. All these 
women received care from the Benign Diseases Sector of the Dis-
cipline of Mastology of the Department of Gynecology of a pub-
lic university hospital. 
The patients were between the ages of 16 and 49 years, and all 
were of reproductive age. Their clinical, gynecological and colpo-
cytological tests were normal, with the exception of the benign 
neoplasm in the breast. Patients with endocrine diseases, preg-
nant women and women who had breastfed within the last twelve 
months were excluded.10,11
This retrospective study involved immunohistochemi-
cal analysis on histopathological material that was obtained by 
means of outpatient surgical procedures between January and 
December 2006. The patients were placed under local anes-
thesia, and lumpectomy was performed with a safety margin 
going into the adjacent breast tissue by at least 1 cm from the 
lesion, and both types of materials obtained (breast lump and the 
breast parenchyma tissue adjacent to the lesion) were evaluated 
histopathologically.10,12 
The biopsies were separated into two groups initially, accord-
ing to the type of tissue to be analyzed. The first group (group A) 
included breast lump material (fibroadenomas), and the second 
group (group B) included the breast parenchyma tissue adjacent 
to the lesion. The whole material was prepared in a paraffin block 
for histopathological analysis. The slides were prepared using a 
primary CD83 antibody and a secondary antibody (CD83 anti-
body SEROTEC MCA 1582), and then analyzed. 
The slides were prepared using a microtome, by taking slices 
of thickness 2 mm to 3 mm from the paraffin block. These par-
affin slices were mounted on slides that had been prepared with 
silane-APTS (3-aminopropyltriethoxysilane). The slides were 
then deparaffinized and hydrated via the following steps: immer-
sion in xylol at 60 °C for 15 minutes; xylol at room temperature 
for 15 minutes; 100% ethanol (three times) for 30 seconds each; 
95% ethanol for 30 seconds; 80% ethanol for 30 seconds; 70% 
ethanol for 30 seconds; and then washing with distilled water.
The next phase in the preparation was antigen recovery from 
the paraffin-embedded tissue samples, which is necessary for most 
of the epitopes investigated.13 This was accomplished by micro-
wave irradiation, in which the slides were incubated and buffered 
with 10 mM citrate (pH 5.0) in a microwave oven at maximum 
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power for two sessions of nine minutes each, with a freezing inter-
val of 20 minutes, followed by washing with distilled water.14 
Subsequently, the slides were subjected to two 10-minute 
baths in 3% hydrogen peroxide (H2O2) in methanol, followed 
by washing with distilled water and buffering using phosphate-
buffered saline (PBS) solution. This was used to block the tissue 
endogenous peroxidase.
The slides were prepared with specific antibodies using the per-
oxidase-antiperoxidase (PAP) complex, via the following steps:15 
the slides were incubated with a specific antibody (diluted in PBS), 
for 16 to 18 hours at 4 °C in a humid chamber;  washed three times 
in PBS for three to five minutes each; incubated with a specific 
secondary antibody (diluted in PBS) for 30 minutes at 37 °C in 
a humid chamber; washed three times with PBS for three to five 
minutes each; incubated with the PAP complex (diluted in PBS) 
for 30 minutes at 37 °C in a humid chamber; and washed three 
times with PBS for three to five minutes each. The antigen binding 
was then revealed after the slides had been incubated in a substrate 
of diaminobenzidine (DAB) solution (60 mg%), and it could be 
observed soon afterwards using an optical microscope. The chest-
nut-gold precipitate was developed as the final product of the reac-
tion on positive control slides. The slides were then washed with 
distilled water for three minutes, dyed with Harris’s hematoxylin 
for one minute and washed with distilled water. They were then 
immersed quickly four times in 0.5% ammonium hydroxide, and 
washed with distilled water; the slides were dehydrated first in 50% 
ethanol, followed by 80% ethanol, 95% ethanol, 100% ethanol and 
finally, three times in xylol. Coverslips were affixed using Entellan, 
for analysis under an ordinary optical microscope.
As previously discussed, the hormonal actions of estrogen 
and progesterone can influence cell proliferation in fibroade-
nomas and breast duct epithelium. Therefore, considering the 
clinical features presented in this study, the sample was further 
divided in two groups in relation to the use of hormonal contra-
ceptives: group C consisted of 21 cases of women who were not 
using hormonal contraceptives, while group D consisted of eight 
women who were using oral hormonal contraceptives. The anal-
ysis of CD83 antigen expression in these cells was accomplished 
by means of random manual counting using optical microscopy, 
and the results were categorized according to whether the anti-
gen was expressed as much or not as much in the adjacent breast 
cells as it was in the fibroadenoma cells. The expression of the 
antigen CD83 was considered positive in the cells in which chest-
nut staining in the cytoplasm was identified, independent of the 
intensity or tonality of the staining, because there is no previous 
knowledge of analyses on this antibody in these tissues. A thou-
sand cells from each case were analyzed, with five hundred from 
the fibroadenoma and five hundred from the adjacent breast tis-
sue, for statistical calculation of the antigen expression. Initially, 
the normal distribution test was done to verify that the data 
obtained presented normal distribution (group A: P = 0.125 and 
group B: P = 0.572). Since the data presented normal distribu-
tion, we used a parametric test (Student’s t test for independent 
groups) for statistical analysis on the results. The value of P < 0.05 
was considered statistically significant. 
reSUltS 
Histopathological material from 29 cases of fibroadenomas 
and adjacent breast tissues were analyzed from 28 women aged 
between 16 and 49 years, with an average age of 27.2 years. Fif-
teen were nulliparous (P0), one had only had one pregnancy 
(P1), six had had two pregnancies (P2), five had had three preg-
nancies (P3) and one had had five pregnancies (P5). Five women 
had a family history of breast cancer: three had an aunt with 
breast cancer; one had a grandmother with breast cancer and 
another had an aunt and a grandmother with breast cancer. The 
great majority of the cases (23) did not have family history of 
breast or ovarian cancers (Table 1). All of the women in the study 
were of reproductive age, and eight of them were using hormonal 
contraceptives. 
Most of the fibroadenomas (19 cases) were solitary, but in 
five cases, the women had two fibroadenomas, and in two cases 
the patients had three fibroadenomas each. In another single case 
there were four lumps, and one other woman presented seven 
fibroadenomas. In nine of the cases of multiple fibroadenomas, 
five were bilateral. The largest diameter of the lesions ranged 
from 0.5 cm to 3 cm (average: 1.52 cm).
Other clinical features, such as age at first childbirth and 
smoking, were considered. However, they did not present statis-
tical relevance (Table 1).
The value of CD83 expression in the fibroadenoma cells and 
in the adjacent breast cells was analyzed. Positive antigen expres-
sion was observed (Figures 1 and 2), on average, in 365.52 (stan-
dard deviation [SD] ± 133.13) of the fibroadenoma cells and in 
189.59 (SD ± 140.75) of the adjacent breast tissue cells (P < 0.001). 
In the fibroadenomas, negative antigen expression or non-expres-
sion was observed in 134.14 (SD ± 133.40) of the cells (Figure 3), 
while in the adjacent breast tissue 310.41 (SD ± 134.85) of the 
cells did not express the CD83 antigen (P < 0.001). From analysis 
on these results, we observed that the difference in CD83 expres-
sion between groups A and B was significant (P < 0.001). Addi-
tionally, the negative expression or non-expression of CD83 was 
also significantly different (P < 0.001). These results confirmed 
that CD83 expression was much more evident in the fibroade-
noma cells (P < 0.001). These values were analyzed in an absolute 
manner, and they are shown in Table 2. 
The influence of the use of oral hormonal contraceptives 
on the cell expression of CD83 was analyzed by using the data 
obtained from groups C and D. The results from these two groups 
were analyzed as above. 
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n Age (years) HStatus BCM FH Parity FP FA FAD (cm) Smoker
1 18 M No No P0 22 1 1.1 No
2 43 M HT No P2 19 1 1.8 Ex 
3 25 M No No P1 20 1 2.3 No
4 38 M LT Aunt P3 26 1 1.0 No
5 38 M LT No P3 2 0.9 No
6 23 M No No P0 18 2 1.0 No
7 43 M CI Aunt P2 25 1 2.0 Ex  
8 36 M VC No P2 1 1.3 No
9 16 M No No P0 1 3.0 No
10 23 M No No P0 26 1 1.7 No
11 39 M VC No P2 21 2 0.9 No
12 43 M LT No P3 22 1 1.2 No
13 39 M LT No P2 22 1 0.8 No
14 45 M LT No P3 21 1 2.5 No
15 45 M HT No P3 1 1.4 No
16 16 M No No P0 21 3 2.4 No
17 49 M LT No P5 28 1 1.3 No
18 38 M LT No P2 1 0.5 No
19 19 M No No P0 2 1.2 No
20 22 M No No P0 1 1.0 No
21 31 M OC No P0 2 1.5 No
22 32 M OC No P0 3 1.2 No
23 19 M OC GMo P1 7 2.0 No
24 38 M OC No P0 1 2.0 No
25 23 M OC Aunt P0 1 2.0 No
26 25 M OC Aunt/GMo P0 1 2.0 No
27 29 M OC No P0 4 1.7 No
28 17 M OC No P0 1 2.5 No
HStatus = hormonal status; BCM = birth-control method; FH = family history of breast cancer; FP = first pregnancy (age in years); FA = fibroadenoma (number in 
each case); FAD = fibroadenoma diameter; M = reproductive age; HT = hysterectomy; LT = surgical contraception; CI = coitus interruption; VC = vasectomy; OC 
= oral contraceptive; relatives: aunt; GMo (grandmother); Ex = former smoker.
Table 1. Clinical factors analyzed in the sample 
Figure 1. Case 9: Fibroadenoma with positive expression 
of CD83 antigen (immunohistochemistry staining, optical 
microscopy - 200 X). 
Figure 2. Case 21: Fibroadenoma with positive expression 
of CD83 antigen (immunohistochemistry staining, optical 
microscopy - 1000 X). 
In group C (i.e. non-users of oral hormonal contracep-
tives), positive CD83 antigen expression was found on average 
in 366.38 (SD ± 130.11) of the fibroadenoma cells and in 189.00 
(SD ± 137.54) of the adjacent breast tissue cells (P < 0.001). The 
antigen expression was negative in 133.14 (SD ± 130.49) of the 
fibroadenoma cells and in 311.00 (SD ± 137.54) of the adjacent 
breast tissue cells (P < 0.001). These results are presented in 
Table 3.
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From analysis on the material from group D (i.e. users of 
oral hormonal contraceptives), we found an average of 363.25 
(SD ± 150.08) cells expressing CD83 in the fibroadenoma, while 
in the adjacent breast tissue, the average was 191.12 (SD ± 136.71) 
cells expressing CD83 (P = 0.044). Non-expression was observed 
in 136.75 (SD ± 150.08) fibroadenoma cells and in 308.87 
(SD ± 136.71) cells in the adjacent breast tissue (P = 0.044). These 
results are presented in Table 4. 
The analysis on the results from groups C and D showed 
that CD83 expression in the fibroadenoma cells was more evi-
dent than in the adjacent breast tissue cells, and that in both 
groups there was a statistically significant difference in the results 
(respectively P < 0.001 and P = 0.044). In other words, the use of 
hormonal contraceptives did not appear to have an influence on 
CD83 expression in this analysis.
Several clinical factors were also considered, such as age, fam-
ily history of breast cancer, parity, age at first childbirth, diame-
ter of the lump (fibroadenoma), number of fibroadenomas in each 
patient (multiple or solitary) and smoking (Table 1). The age at 
first childbirth and smoking appeared to be homogeneous in the 
samples studied, and therefore lacking in clinical meaning. The 
other observed features were analyzed statistically, and the results 
are shown in Table 5. The only feature that presented statistical rel-
evance in relation to CD83 expression was parity and this was only 
true in relation to the tissue adjacent to the fibroadenoma. 
The CD83 expression in the nulliparous women was positive, 
on average, in 231.08 (SD ± 131.61) cells and in the other women 
who had had at least one pregnancy, it was positive in 135.00 
(SD ± 105.63) cells in the adjacent breast tissue (P = 0.042). 
There was no antigen expression in 268.92 (SD ± 131.61) cells 
in the adjacent breast tissue of the nulliparous women or in 
365.00 (SD ± 105.63) cells in the same tissue of the other women 
(P = 0.042). The analysis on these results in relation to the fibroad-
enoma cells did not reveal significance (Table 5).
Figure 3. Case 23: Fibroadenoma with negative expression of CD83 
antigen (immunohistochemistry staining, optical microscopy - 200 X). 
Table 2. Comparison of the CD83 antigen expression in fibroadenoma 
cells (FA) (group A) and adjacent normal breast tissue (BT) (group B), in 
absolute numbers; n = 29
Confidence interval statistics
Variable Mean/SD ± minimum maximum T P
FA positive 365.52
133.13
(73.10%)
± 314.88
(62.97%)
416.16
(83.23%)
BT positive 189.59
140.75
(37.92%)
± 138.29
(27.66%)
240.88
(48.18%)
5.662 < 0.001
FA negative 134.14
133.40
(26.83%)
± 83.39
(16.68%)
184.88
(36.98%)
BT negative 310.41
134.85
(62.08%)
± 259.12
(51.82%)
361.71
(72.34%)
5.671 < 0.001
SD = standard deviation; FA = fibroadenoma; BT = breast tissue; T = Student’s t test.
Table 3. Comparison of CD83 expression in fibroadenoma cells (FA) 
and adjacent normal breast tissue (BT), in absolute numbers; group C 
(n = 21) non-users of contraceptives
Confidence interval statistics
Variable Mean/SD ± minimum maximum T P
FA positive 366.38
130.11
(73.28%)
± 307.16
(61.43%)
425.60
(85.12%)
BT positive 189.00
140.75
(37.80%)
± 126.39
(25.28%)
251.61
(50.32)
5.093 < 0.001
FA negative 133.14
133.49
(26.62%)
± 73.74
(14.75%)
192.54
(38.51%)
BT negative 311.00
137.54
(62.20%)
± 248.39
(49.68%)
373.61
(74.72%)
5.104 < 0.001
SD = standard deviation; FA = fibroadenoma; BT = breast tissue; T = Student’s t test.  
Table 4. Comparison of CD83 expression in fibroadenoma 
cells (FA) and adjacent normal breast tissue (BT), in absolute 
numbers; group D (n = 8), using hormonal contraceptives
Confidence interval statistics
Variable Mean/SD ± minimum maximum T P
FA positive 363.25
150.08
(72.65%)
± 237.78 488.72
BT positive 191.12
136.71
(38.22%)
± 76.83 305.42 2.459 0.044
FA negative 136.75
150.08
(27.35%)
± 11.28 262.22
BT negative 308.87
136.71
(61.77%)
± 194.58 423.16 2.459 0.044
SD = standard deviation; FA = fibroadenoma; BT = breast tissue; T = Student’s t test  
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Dendritic cell maturation is crucial for the initiation of 
immune defenses. This process is characterized by a reduction 
in the capacity to capture antigens and an increase in the capac-
ity to express MHC molecules and costimulators. Maturation 
occurs when there is an interaction between the dendritic cell 
and a T cell, followed by a loss of phagocytic ability, and increased 
strength of interaction with the T lymphocyte receptors; this is 
due to increased adhesion and signaling capacity with costimula-
tory molecules.20,21 Mature and differentiated dendritic cells that 
highly express CD83 can be obtained by culturing dendritic cells 
with granulocyte/macrophage colony-stimulating factor (GM-
CSF), interleukin-4 (IL-4) and monocyte-conditioned medium 
(MCM). These cells have a greater capacity to present antigens 
and increased mixed leukocyte reaction-stimulatory function.22 
Identification of a human immune response against neoplasms 
appears to have an important role in the evolution of neoplastic 
lesions, and several aspects of the activation of these immune 
responses and their mechanisms have been elucidated over the last 
few years. However, many features remain unknown, including the 
magnitude of the immune response against tumors and the possi-
ble clinical applications and effective treatments. The importance of 
dendritic cell action and activation in the immune system has been 
implicated in several diseases, for example: viral infection,23 para-
sitic infections such as malaria,24 malignant diseases such as col-
orectal cancer,25 Chlamydia infections26 and allergic diseases such 
as atopic eczema and asthma.27,28 Many possibilities may open up 
through studies on the immune system and dendritic cells, thereby 
making it possible to discover new treatments and vaccines.
Table 5. Analysis of CD83 expression in the fibroadenoma cells (FA) (group A) and in the adjacent breast tissue (BT) (group B), in relation 
to the clinical features studied (age; family history of breast cancer; parity; number of fibroadenomas in each case; lump diameter)
Variable FA positive FA negative BT positive BT negative
Age (years)
≤ 30 years 349.23 ± 135.65 150.00 ± 136.37 216.77 ± 97.99 283.23 ± 97.99
> 30 years 372.53 ± 136.26 127.47 ± 136.26 147.40 ±141.32 352.60 ± 141.32
P 0.655 0.666 0149 0.149
Family history
Negative 373.17 ± 127.08 126.39 ± 127.41 190.09 ± 131.25 309.91 ± 131.25
Positive 309.00 ± 167.58 191.00 ± 167.58 131.40 ± 93.78 368.60 ± 93.78
P 0.341 0.339 0.335 0.335
Parity
Nulliparous 391.85 ± 109.37 107.38 ± 109.93 231.08 ± 131.61 268.92 ± 131.61
Others 335.60 ± 150.94 164.40 ± 150.94 135.00 ± 105.63 365.00 ± 105.63
P 0.276 0.27 0.042 0.042
Number of fibroadenomas
Only 1 344.00 ± 134.30 156.00 ± 134.30 166.21 ± 118.70 333.79 ± 118.70
More than 1 399.11 ± 132.92 99.78 ± 133.56 207.89 ± 143.23 292.11 ± 143.23
P 0.318 0.31 0.424 0.424
Fibroadenoma diameter (cm)
≤ 1.5 374.53 ± 136.49 124.80 ± 136.97 171.47 ± 151.76 328.53 ± 151.76
> 1.5 346.92 ± 134.91 153.08 ± 134.91 189.00 ± 92.98 311.00 ± 92.98
P 0.596 0.588 0.712 0.712
FA = fibroadenoma; BT = breast tissue.
DISCUSSION
The main objective of this study was to identify CD83 expression 
in fibroadenoma cells, since the expression of this antigen is an 
important marker of maturation of the dendritic cell population 
and, consequently, an indication of immune activity. The immune 
system has the capacity to react against neoplasms, and the human 
immune response against tumor cells mainly occurs through 
activation of cytotoxic T lymphocytes (CD8+). This activation 
depends on recognition of foreign antigens associated with MHC 
Class I on the surface of the dendritic cell. Dendritic cells have an 
antigen-presenting function, and they capture tumor antigens and 
introduce them to the lymphocyte after migration to the second-
ary lymph nodes where the immune response begins.16 There is a 
change in the receptor repertoire of the dendritic cell that facilitates 
its ability to change its location depending on its maturation phase. 
This increases its effectiveness at finding, capturing and presenting 
antigens.17 Dendritic cells have the capacity to do this in a way that 
is linked to their maturation, because antigen expression, such as 
CD83, increases in parallel with the antigen presentation function 
of dendritic cells.18 Lipopolysaccharide (LPS) increases the endo-
cytic activity of dendritic cells and induces CD83 expression. LPS 
also increases the production of TNF-alpha and E2 prostaglan-
din (PGE2). Some endotoxins can inhibit these actions of LPS, a 
phenomenon referred to as tolerance to LPS; this reduces the pro-
duction of TNF-alpha, interleukin-10 (IL-10) and interleukin-12 
(IL-12). In vitro, treatment with TNF-alpha and PGE2 totally res-
cues CD83 expression and interferon-gamma (IFN-g) release by 
inducing dendritic cell activity in mixed leukocyte reactions.19 
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There are many reasons why the immune response against 
tumors may be unsuccessful, and some of these reasons are 
already known. Every tumor cell expresses MHC class I, but 
in some situations, this expression is downregulated and the 
cytolytic T cells are not capable of recognizing them. In tumors 
with fast growth, there is substantial genetic instability because 
of the discharge rate of mitoses and loss of the expression of anti-
gens capable of activating the immune system. In such situations, 
cytolytic T cells cannot be activated because, usually, the tumor 
cell does not express MHC class II or many other costimulatory 
molecules that are essential for activation of helper T cells. Many 
tumor antigens are self-tolerated, and they are thus not recog-
nized as foreign. These immune features and others indicate that 
it is necessary to maximize the current knowledge about these 
lesions, so that in the future, treatments that will provide the best 
treatment of the lesion in a specific manner can be selected.
Because of this, knowledge of CD83 expression in breast 
fibroadenoma cells becomes very important. The present study 
shows that there is increased CD83 expression in fibroadenomas, 
compared with the adjacent breast tissue (P < 0.001), and this 
could represent more intense immune activity against these 
benign tumors, probably mediated by antigen-presenting cells 
(APC). Since there have been no previous evaluations of this 
antigen in breast tumors, we can propose that CD83 expression 
is an indicator of the prognosis of lesions and/or is indicative of 
the future risk of malignant neoplasm. This may even be a good 
indicator of prognosis for the lesions considered in this study, 
and suggests that, perhaps in these CD83+ tumors, APC can act 
with greater effectiveness and, consequently, the immune system 
can be activated with greater speed and specificity. This knowl-
edge, together with that obtained through future research, may 
result in new perspectives in relation to effective immunother-
apy against this cancer. Positive expression of the antigen CD83 
in dendritic cells indicates maturation of these cells and, per-
haps, also has the same meaning when expressed in the fibroad-
enoma epithelial cells, thereby indicating important differentia-
tion between this neoplasia and normal breast tissue.
This study evaluated clinical features that could influence 
this CD83 expression. The results showed that, of the factors ana-
lyzed, the only one that influenced CD83 expression in breast tis-
sue adjacent to the fibroadenoma was the patient’s parity. Positive 
expression of CD83 was more evident in the adjacent breast tissue 
of the nulliparous women (P = 0.042). There is a coherent asso-
ciation between these data and previous knowledge, which indi-
cates the age at the first childbirth has an influence on breast can-
cer risk. Having the first childbirth at a younger age reduces the 
risk of breast cancer.29 Additionally, large parity can reduce this 
risk.30 The first pregnancy indicates the time at which the phys-
iological maturation of the breast gland is completed, presum-
ably from the intense estrogen, progesterone, HCG and prolactin 
stimulation. The maturation begins with ductal ramification and 
growth of the lobule-alveolar structure, until the formation of 
multiple alveoli is complete and consequent glandular epithelium 
proliferation occurs. This development is followed by the forma-
tion of glandular structures, lobule-alveolar system maturation 
and secretory epithelium maturation.31 These breast tissue modi-
fications, associated with obstetric factors, affect cytological char-
acteristics and the risk of breast cancer, thus indicating that the 
gland is influenced by pregnancy and may develop the capacity to 
recognize antigens and activate the immune system.
CONCLUSIONS
The expression of CD83 in the fibroadenoma cells was positive 
and greater than in the breast tissue adjacent to the lump (P < 
0.001), when analyzed by means of immunohistochemistry. New 
studies should be conducted in order to define the clinical mean-
ing of this result and investigate the possibility that this knowl-
edge may be important in the pursuit of new immune therapies 
against breast tumors. 
The expression of CD83 in the breast tissue adjacent to the 
fibroadenoma was influenced by whether the patient was nullip-
arous or had already had at least one full term pregnancy, and it 
was significantly greater in nulliparous women (P = 0.042). In 
this context, the repercussions of pregnancy in breast tissue may 
affect the immune response; this needs to be better character-
ized, given that CD83 expression in breast tissue adjacent to the 
fibroadenoma was influenced by the patient’s history of preg-
nancy (P = 0.042).
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